Radioimmunological imaging of metastatic prostatic cancer with 111indium-labeled monoclonal antibody PAY 276

R. J. Babaian, J. L. Murray, L. M. Lamki, T. P. Haynie, Evan M Hersh, M. G. Rosenblum, H. J. Glenn, M. W. Unger, D. J. Carlo, A. C. von Eschenbach

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

A total of 25 patients with histologically proved adenocarcinoma of the prostate, whose disease was staged clinically as D2 by appropriate radiographic and nuclear medicine studies, received increasing doses of PAY 276, an antiprostatic acid phosphatase monoclonal antibody for radioimmunological imaging. The patients were divided into 5 groups of 5. Groups 1 through 5 received an infusion of 5, 10, 20, 40 or 80 mg. monoclonal antibody, respectively, 1 mg. of which was labeled to 5 mCi. of 111indium, while stable monoclonal antibody was added to achieve the desired antibody concentration. No patient had an allergic reaction, and no significant change in serial hemoglobin levels, platelet count, chemistry profile or results of urinalyses was noted. The monoclonal antibody scan visualized at least 1 lesion in 19 of 25 patients (76 per cent): 4 in groups 1 and 2, and all 15 in groups 3 to 5. With results of conventional radiography and bone scintigraphy considered definitive for metastases, monoclonal antibody scans detected 7 of 32 metastases (21.8 per cent) in group 3 (20 mg.), 31 of 58 (53.4 per cent) in group 4 (40 mg.) and 101 of 134 (75.4 per cent) in group 5 (80 mg). In group 5 the incidence of false positive and false negative scans was 2.3 per cent (3 of 132) and 24.6 per cent (33 of 134), respectively. The detection of metastatic lesions increased as the concentration of unlabeled monoclonal antibody increased. Radioimmunological imaging of prostatic cancer with antiprostatic acid phosphatase monoclonal antibody seems to be feasible.

Original languageEnglish (US)
Pages (from-to)439-443
Number of pages5
JournalJournal of Urology
Volume137
Issue number3
StatePublished - 1987
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Monoclonal Antibodies
Acid Phosphatase
Neoplasm Metastasis
Urinalysis
Nuclear Medicine
Platelet Count
Radiography
Radionuclide Imaging
Prostate
Hypersensitivity
Hemoglobins
Adenocarcinoma
Bone and Bones
Antibodies
Incidence

ASJC Scopus subject areas

  • Urology

Cite this

Babaian, R. J., Murray, J. L., Lamki, L. M., Haynie, T. P., Hersh, E. M., Rosenblum, M. G., ... von Eschenbach, A. C. (1987). Radioimmunological imaging of metastatic prostatic cancer with 111indium-labeled monoclonal antibody PAY 276. Journal of Urology, 137(3), 439-443.

Radioimmunological imaging of metastatic prostatic cancer with 111indium-labeled monoclonal antibody PAY 276. / Babaian, R. J.; Murray, J. L.; Lamki, L. M.; Haynie, T. P.; Hersh, Evan M; Rosenblum, M. G.; Glenn, H. J.; Unger, M. W.; Carlo, D. J.; von Eschenbach, A. C.

In: Journal of Urology, Vol. 137, No. 3, 1987, p. 439-443.

Research output: Contribution to journalArticle

Babaian, RJ, Murray, JL, Lamki, LM, Haynie, TP, Hersh, EM, Rosenblum, MG, Glenn, HJ, Unger, MW, Carlo, DJ & von Eschenbach, AC 1987, 'Radioimmunological imaging of metastatic prostatic cancer with 111indium-labeled monoclonal antibody PAY 276', Journal of Urology, vol. 137, no. 3, pp. 439-443.
Babaian, R. J. ; Murray, J. L. ; Lamki, L. M. ; Haynie, T. P. ; Hersh, Evan M ; Rosenblum, M. G. ; Glenn, H. J. ; Unger, M. W. ; Carlo, D. J. ; von Eschenbach, A. C. / Radioimmunological imaging of metastatic prostatic cancer with 111indium-labeled monoclonal antibody PAY 276. In: Journal of Urology. 1987 ; Vol. 137, No. 3. pp. 439-443.
@article{3f91631591a445f5a33c2f0a7cbf2462,
title = "Radioimmunological imaging of metastatic prostatic cancer with 111indium-labeled monoclonal antibody PAY 276",
abstract = "A total of 25 patients with histologically proved adenocarcinoma of the prostate, whose disease was staged clinically as D2 by appropriate radiographic and nuclear medicine studies, received increasing doses of PAY 276, an antiprostatic acid phosphatase monoclonal antibody for radioimmunological imaging. The patients were divided into 5 groups of 5. Groups 1 through 5 received an infusion of 5, 10, 20, 40 or 80 mg. monoclonal antibody, respectively, 1 mg. of which was labeled to 5 mCi. of 111indium, while stable monoclonal antibody was added to achieve the desired antibody concentration. No patient had an allergic reaction, and no significant change in serial hemoglobin levels, platelet count, chemistry profile or results of urinalyses was noted. The monoclonal antibody scan visualized at least 1 lesion in 19 of 25 patients (76 per cent): 4 in groups 1 and 2, and all 15 in groups 3 to 5. With results of conventional radiography and bone scintigraphy considered definitive for metastases, monoclonal antibody scans detected 7 of 32 metastases (21.8 per cent) in group 3 (20 mg.), 31 of 58 (53.4 per cent) in group 4 (40 mg.) and 101 of 134 (75.4 per cent) in group 5 (80 mg). In group 5 the incidence of false positive and false negative scans was 2.3 per cent (3 of 132) and 24.6 per cent (33 of 134), respectively. The detection of metastatic lesions increased as the concentration of unlabeled monoclonal antibody increased. Radioimmunological imaging of prostatic cancer with antiprostatic acid phosphatase monoclonal antibody seems to be feasible.",
author = "Babaian, {R. J.} and Murray, {J. L.} and Lamki, {L. M.} and Haynie, {T. P.} and Hersh, {Evan M} and Rosenblum, {M. G.} and Glenn, {H. J.} and Unger, {M. W.} and Carlo, {D. J.} and {von Eschenbach}, {A. C.}",
year = "1987",
language = "English (US)",
volume = "137",
pages = "439--443",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Radioimmunological imaging of metastatic prostatic cancer with 111indium-labeled monoclonal antibody PAY 276

AU - Babaian, R. J.

AU - Murray, J. L.

AU - Lamki, L. M.

AU - Haynie, T. P.

AU - Hersh, Evan M

AU - Rosenblum, M. G.

AU - Glenn, H. J.

AU - Unger, M. W.

AU - Carlo, D. J.

AU - von Eschenbach, A. C.

PY - 1987

Y1 - 1987

N2 - A total of 25 patients with histologically proved adenocarcinoma of the prostate, whose disease was staged clinically as D2 by appropriate radiographic and nuclear medicine studies, received increasing doses of PAY 276, an antiprostatic acid phosphatase monoclonal antibody for radioimmunological imaging. The patients were divided into 5 groups of 5. Groups 1 through 5 received an infusion of 5, 10, 20, 40 or 80 mg. monoclonal antibody, respectively, 1 mg. of which was labeled to 5 mCi. of 111indium, while stable monoclonal antibody was added to achieve the desired antibody concentration. No patient had an allergic reaction, and no significant change in serial hemoglobin levels, platelet count, chemistry profile or results of urinalyses was noted. The monoclonal antibody scan visualized at least 1 lesion in 19 of 25 patients (76 per cent): 4 in groups 1 and 2, and all 15 in groups 3 to 5. With results of conventional radiography and bone scintigraphy considered definitive for metastases, monoclonal antibody scans detected 7 of 32 metastases (21.8 per cent) in group 3 (20 mg.), 31 of 58 (53.4 per cent) in group 4 (40 mg.) and 101 of 134 (75.4 per cent) in group 5 (80 mg). In group 5 the incidence of false positive and false negative scans was 2.3 per cent (3 of 132) and 24.6 per cent (33 of 134), respectively. The detection of metastatic lesions increased as the concentration of unlabeled monoclonal antibody increased. Radioimmunological imaging of prostatic cancer with antiprostatic acid phosphatase monoclonal antibody seems to be feasible.

AB - A total of 25 patients with histologically proved adenocarcinoma of the prostate, whose disease was staged clinically as D2 by appropriate radiographic and nuclear medicine studies, received increasing doses of PAY 276, an antiprostatic acid phosphatase monoclonal antibody for radioimmunological imaging. The patients were divided into 5 groups of 5. Groups 1 through 5 received an infusion of 5, 10, 20, 40 or 80 mg. monoclonal antibody, respectively, 1 mg. of which was labeled to 5 mCi. of 111indium, while stable monoclonal antibody was added to achieve the desired antibody concentration. No patient had an allergic reaction, and no significant change in serial hemoglobin levels, platelet count, chemistry profile or results of urinalyses was noted. The monoclonal antibody scan visualized at least 1 lesion in 19 of 25 patients (76 per cent): 4 in groups 1 and 2, and all 15 in groups 3 to 5. With results of conventional radiography and bone scintigraphy considered definitive for metastases, monoclonal antibody scans detected 7 of 32 metastases (21.8 per cent) in group 3 (20 mg.), 31 of 58 (53.4 per cent) in group 4 (40 mg.) and 101 of 134 (75.4 per cent) in group 5 (80 mg). In group 5 the incidence of false positive and false negative scans was 2.3 per cent (3 of 132) and 24.6 per cent (33 of 134), respectively. The detection of metastatic lesions increased as the concentration of unlabeled monoclonal antibody increased. Radioimmunological imaging of prostatic cancer with antiprostatic acid phosphatase monoclonal antibody seems to be feasible.

UR - http://www.scopus.com/inward/record.url?scp=0023117414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023117414&partnerID=8YFLogxK

M3 - Article

C2 - 3820371

AN - SCOPUS:0023117414

VL - 137

SP - 439

EP - 443

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -